Physician profile
Tim M Simon
NPI 1376523316
$4,412.15
in general payments reported to CMS, 2019-2025
38 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $549 · 2021: $1,325 · 2022: $110 · 2023: $612 · 2024: $504 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.29 | 2020-2024 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $495.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $418.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $356.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.94 | 2020-2021 | |
| Amgen INC. | $259.68 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $259.17 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $257.54 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $151.17 | 2019-2020 | |
| Horizon Therapeutics Plc | $139.43 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $136.50 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.28 | 2020-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $78.68 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $77.43 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $75.57 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.